The research group of Professor Christian Blank is looking for a motivated and talented Computational Biologist to join our team at the Netherlands Cancer Institute (NKI).
Neoadjuvant Immunotherapies in stage III disease are currently the second wave in cancer immunotherapies, inducing even higher response rates and allowing response evaluation in the individual patient. Our group was the first showing that neoadjuvant immunotherapy is superior to adjuvant therapy in expanding tumor resident T cells (Blank et al., Nat Med 2018). We also identified a well-tolerated combination therapy benefitting almost 80% of stage III melanoma patients (Rozeman et al. Lancet Oncology 2019, Rozeman et al. Nat Med 2020). Currently we are testing whether we can omit surgery in these patients achieving major pathologic response upon the neoadjuvant immunotherapy.
The next step towards personalized immunotherapy, that we aim for, is identifying baseline signatures discriminating responders from non-responders. To do so, we analyse baseline tumor biopsies (DNAseq, RNAseq, spatial tissue protein profiling by NanoString DSP microscopy), serum cytokine levels, and the patients’ microbiome.
The goal of this project is to identify baseline signatures associated with response and adverse events. This will allow an improved patient selection, and allow gaining a deeper understanding of mechanisms of resistance to neoadjuvant immunotherapy, leading to alternative combination therapies in patients with unfavourable tumor signatures.
The computational biologist on this project will perform integrative analyses of datasets generated from our investigator-initiated trials, aiming at understanding requirements for response to current neoadjuvant immunotherapies and propose new combination therapies correcting the unfavourable tumor microenvironment in non-responders.
Bioinformatician (50%) , University of Basel, Switzerland, about 12 hours ago
The Brain Tumor Immunotherapy Group (Department of Biomedicine, University of Basel and University Hospital Basel) is seeking a Master's degree or Ph.D. level bioinformatician. Our group is devote...
Bioinformatician (M/F/D) In Bioinformatics Core Unit (# Of Pos: 7), St. Anna Kinderkrebsforschung GmbH / St. Anna Children´s Cancer Research Institute, Austria, 13 days ago
We are extending our bioinformatics team and are seeking for an enthusiastic bioinformatician who would like to build and advance their career in translational cancer genomics. You will conduct an...
Innovation Manager For The Immuno Oncology Program Of The Leuven Cancer Institute, Katholieke Universiteit Leuven, Belgium, 11 days ago
(ref. OZK-2021-43) Laatst aangepast : 6/05/2021 The Leuven Cancer Institute (LKI) is an organization that strategically coordinates all activities related to cancer research, treatment and care at...
Head Of Discovery, RemedyBio, Ireland, 18 days ago
Head of Discovery RemedyBio Background RemedyBio is pioneering new classes of immunotherapy based on a powerful mass scale single cell analytical technology. Our Nanoreactor platform enables us to...
Med/04 Patologia Generale;, Università, Italy, 19 days ago
Extracellular vesicles in cancer development progression and drug resistance: potential biomarkers and therapeutic targets (PRIN_Protocol 2017EKMFTN_005) Teaching commitment – the researcher will ...
Announcement Of The Call For Applications Under The Program: Call No. 02 18 053 For International..., Univerzita Palackého v Olomouci, Czech, 18 days ago
Mobility description: The successful candidate will participate in ongoing projects in the position of Junior research scientist (Post-doc) as a full-time employee (40 hours/week) of the Palacký U...